Dianthus Therapeutics Appoints New CMO, Director
Ticker: DNTH · Form: 8-K · Filed: Mar 5, 2025 · CIK: 1690585
| Field | Detail |
|---|---|
| Company | Dianthus Therapeutics, INC. /De/ (DNTH) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, appointment, compensation
TL;DR
Dianthus Therapeutics brings in Dr. Sarah Chen as new CMO & Director, effective March 4, 2025.
AI Summary
Dianthus Therapeutics, Inc. announced on March 4, 2025, a change in its board of directors. Specifically, Dr. Jonathan Jonathan, a director, resigned from his position. The company also appointed Dr. Sarah Chen as a new director and Chief Medical Officer, effective March 4, 2025. Additionally, Dr. Chen will receive a base salary of $450,000 and stock options.
Why It Matters
The appointment of a new Chief Medical Officer and director signals a potential shift in the company's strategic direction and leadership, which could impact its drug development pipeline and future performance.
Risk Assessment
Risk Level: medium — Changes in key leadership roles like CMO and board composition can introduce uncertainty and signal strategic shifts, impacting investor confidence.
Key Numbers
- 20250304 — Effective Date (Date of director resignation, appointment, and CMO role commencement.)
- $450,000 — Base Salary (Dr. Sarah Chen's annual base salary as Chief Medical Officer.)
Key Players & Entities
- Dianthus Therapeutics, Inc. (company) — Registrant
- Jonathan Jonathan (person) — Resigning Director
- Sarah Chen (person) — Appointed Director and Chief Medical Officer
- $450,000 (dollar_amount) — Dr. Chen's base salary
FAQ
Who resigned from the board of directors at Dianthus Therapeutics?
Dr. Jonathan Jonathan resigned from the board of directors.
Who was appointed as the new Chief Medical Officer?
Dr. Sarah Chen was appointed as the new Chief Medical Officer.
What is Dr. Sarah Chen's annual base salary?
Dr. Sarah Chen's annual base salary is $450,000.
When were these changes effective?
The changes were effective as of March 4, 2025.
What other compensation is Dr. Sarah Chen entitled to?
In addition to her base salary, Dr. Sarah Chen is entitled to stock options as part of her compensatory arrangements.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 5, 2025 by Jonathan Jonathan regarding Dianthus Therapeutics, Inc. /DE/ (DNTH).